EVH

EVH

USD

Evolent Health Inc Class A Common Stock

$8.450-0.100 (-1.170%)

Precio en Tiempo Real

Healthcare
Health Information Services
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$8.550

Máximo

$8.665

Mínimo

$8.385

Volumen

0.70M

Fundamentos de la Empresa

Capitalización de Mercado

1.0B

Industria

Health Information Services

País

United States

Estadísticas de Negociación

Volumen Promedio

2.24M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $7.06Actual $8.450Máximo $33.63

Informe de Análisis de IA

Última actualización: 27 may 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

EVH: Evolent Health Inc Class A Common Stock – Decoding Recent Trends and Future Signals

Stock Symbol: EVH Generate Date: 2025-05-27 14:39:13

Let's break down what's been happening with Evolent Health and what the numbers might be telling us.

Recent News Buzz: What's the Vibe?

The news around Evolent Health lately has been a bit of a mixed bag, but leans generally positive. We saw JMP Securities, a notable firm, reiterate their "Market Outperform" rating on EVH, keeping a $13 price target. That's a strong vote of confidence, suggesting they believe the stock will do better than the overall market.

On the flip side, Truist Securities also maintained a "Buy" rating, which is good, but they did trim their price target slightly from $15 to $14. This isn't a huge red flag, but it shows a slight adjustment in expectations from one analyst.

Beyond analyst ratings, Evolent announced a new independent nominee, Shawn Guertin, to its Board of Directors. Board appointments can signal strategic shifts or a strengthening of governance, which is usually seen as a positive. The company also set a date for its first-quarter 2025 financial results release. This upcoming earnings report is a big deal; it's when we'll get the real picture of how the company is performing financially.

Overall, the sentiment from these headlines is cautiously optimistic. Analysts still like the stock, and there's some corporate activity, but everyone's waiting for those earnings numbers.

Price Check: What's the Stock Been Doing?

Looking at the last 30 days of trading, EVH has seen quite a ride. Back in late February, it was hovering around the $8.50-$9.00 mark. We then saw a pretty steady climb through March and early April, pushing past $10.00. For instance, on April 2nd, it hit $10.07, and by April 10th, it was at $9.89.

However, since mid-April, the stock has been on a noticeable downtrend. It dipped from around $10.00 to the low $9s, then further into the $8s. Most recently, on May 27th, the price was $7.43. This is a significant drop from its recent highs and even below its starting point in late February. The trading volume has been quite varied, with some days seeing much higher activity, especially during the sharper moves. For example, on May 9th, when the price dropped significantly, volume spiked to over 5.4 million shares.

Comparing the current price of $7.43 to the recent trend, it's clear the stock has been moving downwards. This puts it very close to its 52-week low of $7.06.

Now, let's look at the AI's future predictions. AIPredictStock.com's model suggests a positive shift:

  • Today's Prediction: +3.64%
  • Next Day's Prediction: +2.51%
  • The Day after next day's Prediction: +3.15%

These predictions, if accurate, would mean a reversal of the recent downward trend, pushing the stock back up. The AI also projects an upward trend with a potential target price of $10.48.

Outlook & Ideas: Putting It All Together

Given the recent news, the price action, and the AI's predictions, the situation for EVH is quite interesting. The stock has taken a hit recently, pushing it down to levels near its 52-week low. This could be seen as a potential "undervalued gem" by some, especially considering its P/E ratio of 5.0x is well below the industry average of 7.6x.

The recent analyst ratings, while slightly adjusted by Truist, still maintain a "Buy" or "Market Outperform" stance. This suggests that despite the recent price dip, professional analysts still see value.

Crucially, the AI model from AIPredictStock.com is forecasting a significant rebound, with positive price movements predicted for the next few days and a longer-term target of $10.48. This strong AI confidence (74.6%) and the prediction of an upward trend are notable. The AI also points to strong buying pressure, with trading volume being 8.4 times the average.

So, what does this suggest? The current situation seems to favor potential buyers, suggesting a possible 'buy' or 'accumulate' window. The stock is trading very close to a support level ($7.20), which the AI highlights as a strong buying opportunity.

Potential Entry Consideration: If you're considering EVH, a potential entry area might be around the current price of $7.43, or even on a slight dip towards the $7.20 support level. The AI's prediction of an immediate upward movement, combined with the stock being near its 52-week low, makes this level look interesting for those who believe in a rebound.

Potential Exit/Stop-Loss Consideration: For managing risk, a potential stop-loss could be set just below the 52-week low, perhaps around $6.48. This would help limit potential losses if the downward trend continues unexpectedly. On the upside, if the AI's predictions hold true, a take-profit target could be around $7.34 in the very short term, or looking further out, the AI's projected target of $10.48 could be a longer-term goal.

Company Context

Evolent Health operates in the Health Information Services sector, focusing on managing care for people with complex conditions. They offer an integrated platform for health plan administration and use technology like their Identifi system and Machinify Auth, which leverages AI. This means their business is deeply tied to healthcare trends and the adoption of technology in that space. The upcoming Q1 2025 financial results will be key to understanding if their business model is translating into strong financial performance, especially given the reported negative revenue growth (-24.4%) and low Return on Equity (-9.2%). Also, keep in mind their debt-to-equity ratio is a bit high at 77.08.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and past performance is not indicative of future results. Always conduct your own thorough research and consult with a qualified financial professional before making any investment decisions.

Noticias Relacionadas

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Evolent Health, Maintains $13 Price Target

JMP Securities analyst Constantine Davides reiterates Evolent Health with a Market Outperform and maintains $13 price target.

Ver más
JMP Securities Reiterates Market Outperform on Evolent Health, Maintains $13 Price Target
PR Newswire

Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors

Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today...

Ver más
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
PR Newswire

Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025

Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will...

Ver más
Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025
Analyst Upgrades

Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $14

Truist Securities analyst Jailendra Singh maintains Evolent Health with a Buy and lowers the price target from $15 to $14.

Ver más
Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $14

Predicción de IABeta

Recomendación de IA

Alcista

Actualizado el: 13 jun 2025, 00:13

BajistaNeutralAlcista

69.6% Confianza

Riesgo y Negociación

Nivel de Riesgo3/5
Riesgo Medio
Adecuado Para
Valor
Guía de Negociación

Punto de Entrada

$8.44

Toma de Ganancias

$9.04

Stop Loss

$7.61

Factores Clave

PDI 9.7 está por encima de MDI 6.8 con ADX 10.5, lo que sugiere una tendencia alcista
El volumen de operaciones es 6.6 veces el promedio (20,069), lo que indica una presión de compra extremadamente fuerte
El MACD 0.0042 está por encima de la línea de señal -0.0018, lo que indica un cruce alcista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.